Cancer Medications Thalomid & Revlimid Class Action Settlement

UPDATE: The Cancer Medications Thalomid & Revlimid Class Action Settlement was granted final approval by the court on October 2, 2020. Please note that claims will not be paid until after the claim submission deadline. Top Class Actions will continue to provide updates as we learn more.

A $34 million settlement has been reached between drug maker Celgene and customers who alleged that the company engaged in a price fixing scheme to raise the cost of cancer medications.

Class Members include all of those patients or third-party payors who paid for cancer medications Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before May 20, 2020.

The Celgene cancer medications class action lawsuit was filed by cancer patients, their families, and insurers. They claimed that the drug maker conspired to keep cheaper, generic versions of these cancer drugs from entering the market in an effort to generate more profit from their name-brand drugs.

According to the Thalomid, Revlimid price fixing class action lawsuit, this caused consumers and insurers to have to pay more for cancer medications than they otherwise would have. 

Patients and insurers had filed multiple lawsuits against Celgene which were then combined into one multidistrict litigation. Celgene denies any wrongdoing, but has agreed to settle the Thalomid, Revlimid class action claims in the interest of avoiding the continued costs and risks of litigation. 

Class Members will be eligible for a proportional share of the settlement fund, after attorneys’ fees are paid from it.

The deadline to submit a claim is Oct. 15, 2020. Claims can be submitted electronically on the settlement website. There are separate claim forms for consumers and third-party payors. 

Some Class Members may have already submitted a claim to participate in a 2019 class action settlement with Celgene. Those consumers are not required to file a new claim, but can submit a supplemental claim for additional purchases of the drugs made after Aug. 1, 2019.

If you have not previously filed a claim, you can file a claim now. If you have previously filed a claim, you can file using a Supplemental Consumer Claim Form which will be available shortly.

Consumers who receive benefits from the cancer medications settlement will give up their right to pursue independent litigation against Celgene over the claims at issue in the Thalomid, Revlimid price fixing class action lawsuit.

Class Members can elect to exclude themselves from the settlement Class if they want to retain their rights to independent litigation and do not want to receive settlement benefits. The deadline for Class Members to exclude themselves from the settlement is Sept. 15, 2020.

Class Members who wish to remain in the settlement Class but do have objections to the terms of the settlement are invited to object by Sept. 15, 2020. Objections can be submitted by writing to the court. 

Class Members are invited but not required to attend a fairness hearing on Sept. 30, 2020. Class Members who object to the settlement may ask to speak at the hearing about their objection.

The rights of all Class Members are affected whether or not they choose to submit a claim for benefits. If a Class Member does nothing, and does not file a benefits claim and does not exclude themselves from the benefits, they will receive no benefits and will give up the right to independently sue Celgene over the claims in the cancer medications price fixing class action lawsuit.

Who’s Eligible

Class Members include all of those patients or third-party payors who paid for Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before May 20, 2020.

Potential Award

Class Members will be eligible for a proportional share of the settlement fund, after attorneys’ fees are paid from it.

Proof of Purchase

No documentation is required at this time, but the Claims Administrator may ask for proof of purchase later in the process.

Claim Form

CLICK HERE TO FILE A CLAIM »

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

10/15/2020

Case Name

In re: Thalomid and Revlimid Antitrust Litigation, Case No. 14-6997 (MCA) (MAH), in the U.S. District Court for the District of New Jersey

Final Hearing

10/01/2020   UPDATED

Settlement Website

www.ThalomidRevlimidLitigation.com

Claims Administrator

In re Thalomid and Revlimid Antitrust Litigation
Settlement Administrator
c/o KCC Class Action Services LLC
P.O. Box 43508
Providence, RI 02940-3508
info@ThalomidRevlimidLitigation.com
1-866-446-1551

Class Counsel

Frank R. Schirripa
Daniel B. Rehns
HACH ROSE SCHIRRIPA & CHEVERIE LLP

Defense Counsel

John E. Schmidtlein
WILLIAMS & CONNOLLY LLP

Read More Lawsuit & Settlement News:

New Seat Belt Recall is Largest in Volvo History

Aetna vs. Cigna: Which Provides Better Long Term Disability Insurance?

Oklahoma Car Dealerships TCPA Class Action Settlement

What Does the New York Lemon Law Cover?